1 Stock Amylyx Still a Buy After Skyrocketing 247%?
Amylyx Pharmaceuticals (AMLX) raised $500M, strengthening its balance sheet. Its experimental drug, avexitide, reduced serious hypoglycemic events by 55% in a phase 3 trial, with potential FDA submission by year-end. Analysts estimate peak U.S. sales at $1.5B. The stock has surged 247% year-to-date, but analysts suggest a pullback to $28-$30 per share for better entry.
How this was made
The 30-second read
Why it matters
The trial data positions Amylyx as a rare biotech with a clear path to a first‑in‑class therapy, likely attracting institutional interest.
Market read
New pivotal data and fresh capital could trigger a short‑term rally, while valuation concerns suggest caution.
What to watch
Potential competition from larger GLP‑1 players and reimbursement uncertainties could temper long‑term growth.
Background
Amylyx raised $500M via a $35.50 per share offering, providing capital for avexitide development.
Ticker impact
Phase 3 Lucidity trial of avexitide reduced serious hypoglycemic events by 55% vs placebo, meeting primary and all secondary endpoints.
Potential upside of 15‑20% if the stock pulls back to $28‑30 and then rallies on FDA filing expectations.
First disclosure of robust Phase 3 results for a novel GLP‑1 therapy in an unmet market; analysts project $1.5B peak sales.
Market effects
Strengthens the GLP‑1 biotech niche and may lift peer valuations in metabolic disorder space.
Positive for U.S. biotech investors; limited immediate effect on broader markets.
Highlights growing interest in novel obesity/diabetes therapies worldwide.
Counterpoint
The $500M dilution and high valuation may limit upside; investors may wait for FDA filing before committing.
Key entities
- companyAmylyx Pharmaceuticals
NASDAQ‑listed biotech developing avexitide for post‑bariatric hypoglycemia.
